Sign in
CompletedPhase 2

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Key facts

Who runs it
Crinetics Pharmaceuticals Inc.
Where
Ann Arbor, Cleveland, East Providence, Minneapolis, Morehead City, Pasadena, Philadelphia, and St Louis, United StatesSee the 8 sitesAlso in 6 other countries, 17 sites
Status
Completed
Phase
Phase 2
People taking part
38 people enrolled
Started
3 Jul 2023
Ended
22 Aug 2025
Type of study
Interventional
Treatments tested
  • atumelnant (CRN04894)
Record updated
10 September 2026

Who can take part

Age
16 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Male or female participants ≥18 to 75 years of age at the time of signing the Informed Consent Form (ICF). Participants ≥16 years of age may be included in sites located in the United States
  • Classic 21-hydroxylase deficiency
  • On a stable regimen of glucocorticoid replacement (eg, hydrocortisone, prednisolone, prednisone, methylprednisolone)
  • Compliance with glucocorticoid replacement and mineralocorticoid replacement (if applicable) regimen during the Screening Period
  • Minimum total daily dose of ≥15 mg hydrocortisone (or equivalent). For Cohort 4, a mean daily dose of ≥11 mg/m²/day of hydrocortisone or hydrocortisone equivalents will be used for inclusion
  • If on estrogen therapy (any route), dose must be stable for at least 3 months prior to Screening

Who cannot take part

  • Dexamethasone use within 30 days of Screening for Cohorts 1-3. In Cohort 4, dexamethasone is permitted
  • History of major surgery/surgical therapy for any cause within 4 weeks prior to Screening
  • Diabetes mellitus treated with insulin for less than 6 weeks prior to Screening, or with change in total daily insulin dose by >15% within 6 weeks prior to Screening
  • Participants with hypothyroidism who are not receiving adequate hormone replacement therapy based on thyroid hormone levels measured at the time of Screening
  • History of unstable angina or acute myocardial infarction within 12 weeks prior to Screening or other clinically significant cardiac disease at the time of Screening
  • Use of antiandrogen therapy in the past 3 months (eg, spironolactone, finasteride, cyproterone acetate, flutamide)
  • Use of testosterone, androgen-containing supplements, aromatase inhibitors, or growth hormone
  • History of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
  • Clinically significant unstable medical condition or chronic disease other than CAH
  • History of cancer excluding cured/treated dermal squamous or basal cell carcinoma or cervical carcinoma in situ
  • Known history of illicit drug or alcohol abuse within the last year
  • Poorly controlled diabetes mellitus defined as having a hemoglobin A1c (HbA1c) ≥8.5%(≥69 mmol/mL), or estimated HbA1c based on fructosamine if HbA1c is not evaluable (eg, due to hemoglobinopathies)
  • Diagnosis of any other form of CAH other than classic 21-hydroxylase deficiency
  • Night shift workers or any other reason for abnormal sleep/wake cycles
  • Pregnant or lactating

Where in United States

Also in 6 other countries, 17 sites

  • Ann Arbor, MichiganHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • East Providence, Rhode IslandHospital not named in the registry
  • Minneapolis, MinnesotaHospital not named in the registry
  • Morehead City, North CarolinaHospital not named in the registry
  • Pasadena, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry

About the trial

What the trial wants to find out

The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.

The group in the trial

  • Sequential DoseTreatment being tested

    Sequential, open-label, 12-week fixed-dose cohorts.

    Treatment: atumelnant (CRN04894)

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
Record updated
10 September 2026